The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Should You Treat SSc with Cyclophosphamide or Mycophenolate?

Should You Treat SSc with Cyclophosphamide or Mycophenolate?

May 17, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The blind, randomized controlled trials identified in the review included patients given cyclophosphamide, as well as patients prescribed other drugs or placebo. The duration of treatment with cyclophosphamide was limited to 12 months due to concerns of adverse events. One trial found a clinically and statistically significant improvement in breathlessness in patients taking cyclophosphamide compared with controls. In particular, cyclophosphamide appeared to protect against decreased FVC among patients with worse fibrosis scores. Another trial found a statistically significant improvement measure of quality of life in patients treated with cyclophosphamide when compared with placebo controls. However, many participants withdrew from these trials due to adverse events, treatment failure and participant preference. In particular, patients in the cyclophosphamide treatment groups experienced leukopenia, neutropenia, thrombocytopenia, anemia and nausea.

You Might Also Like
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
  • The Little-Known (But Not Uncommon) SSc-Lupus Overlap Syndrome
Explore This Issue
May 2018
Also By This Author
  • Neutralizing IL-23 and Its Targets May Improve Ankylosing Spondylitis

Shervin Assassi, MD, a rheumatologist at McGovern Medical School at the University of Texas Health Science Center, Houston, spoke with The Rheumatologist about the findings. While noting that, in the U.S., mycophenolate is typically prescribed to these patients, he adds, “It is reasonable to ask what the evidence is to support that decision.” Given prescription practices in the U.S., he thinks the two randomized control trials comparing cyclophosphamide with mycophenolate were of greatest interest. One of the trials was written and published in Chinese, and the other is the well-known Scleroderma Lung Study II published in 2016.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Both cyclophosphamide and myco­phenolate have comparable effects, but mycophenolate is thought to be safer,” Dr. Assassi says. “At this point, we are using mycophenolate based on the results of the 2016 study.”

Call for More Research

The authors concluded the review by suggesting clinical practice guidelines advise clinicians to consider individual patient characteristics when determining treatment. In particular, they suggest that patients with minor or subclinical disease are unlikely to benefit from cyclophosphamide and are likely to experience adverse effects.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Assassi agrees, noting that “one-third of the patients don’t respond to immunosuppression.” Thus, a great need exists to find biomarkers to identify these patients. The current evidence suggests that histological subtype and disease duration can’t be used to predict responsiveness to treatment.

The review described the evidence as low quality due to the limited number of studies in the field. The authors suggest future studies on the use of cyclophosphamide be adequately powered to compare outcomes within different subgroups. They suggest the groups should be large enough to stratify the extent of pulmonary infiltrates as determined by high-resolution computed tomography, as well as skin involvement in patients with SSc. This suggestion is due to the fact that patients with rapidly progressive fibrotic disease may be in the best position to benefit from cyclophosphamide treatment and these patients are not well represented in the current literature. The authors also identify the need for studies on other forms of connective tissue disease. Unfortunately, since these are rare diseases, it will be difficult to perform large studies.

Pages: 1 2 3 | Single Page

Filed Under: Scleroderma Tagged With: cyclophosphamide, Mycophenolate, SSc, Systemic sclerosisIssue: May 2018

You Might Also Like:
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • From the Expert: New Advances in Treatment of Systemic Scleroderma
  • The Little-Known (But Not Uncommon) SSc-Lupus Overlap Syndrome
  • ACR Issues sJIA Recommendations, SSc Classification Criteria

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)